425: Waters Corp. Supplements Merger Disclosures Amid Lawsuits

Waters Corporation filed an 8-K to provide supplemental disclosures for its planned Reverse Morris Trust merger with BD's Biosciences and Diagnostic Solutions business, addressing stockholder litigation.

Summary

• Waters Corporation is proceeding with a Reverse Morris Trust transaction to acquire BD's Biosciences and Diagnostic Solutions business (SpinCo).
• The transaction involves BD distributing SpinCo common stock to its stockholders, followed by a merger where SpinCo becomes a wholly-owned subsidiary of Waters.
• The SEC declared Waters' Form S-4 registration statement effective on December 23, 2025, and the definitive proxy statement/prospectus was mailed to stockholders.
• Two lawsuits and several demand letters from purported Waters stockholders allege that the proxy statement/prospectus omitted material information, rendering it incomplete and misleading.
• Waters denies these allegations but is voluntarily providing supplemental disclosures to moot the claims, minimize delay risks, and avoid litigation costs, without admitting culpability.
• The supplemental disclosures include additional details on the background of the merger, updated financial projections for Waters and SpinCo, and expanded information on valuation analyses (DCF, comparable companies, precedent transactions) and broker target prices.
• The Waters Board of Directors unanimously recommends voting FOR the merger proposals at the special meeting on January 27, 2026.

Sentiment

Score: 6

Explanation: The filing addresses litigation with proactive supplemental disclosures, aiming to keep a strategic merger on track. While litigation is a negative, the company's response and the underlying strategic value of the merger contribute to a moderately positive sentiment.

Positives

• The merger with BD's Biosciences and Diagnostic Solutions business is a strategic move for Waters, anticipated to generate strong revenue and cost synergies.
• Waters management identified synergy opportunities in cross-selling Waters products into research markets, promoting LC-MS in clinical diagnostics, and optimizing logistics, procurement, and related costs.
• The Waters Board of Directors unanimously recommends the merger, indicating strong internal support for the strategic direction.
• Waters is proactively addressing stockholder litigation by providing supplemental disclosures to minimize potential delays and costs, without admitting wrongdoing.

Negatives

• Two lawsuits and several demand letters have been filed by purported stockholders alleging that the proxy statement/prospectus for the merger was incomplete and misleading.
• The company is incurring costs and management attention to address these legal challenges, even if it believes the claims are without merit.

Risks

• One or more closing conditions to the transaction may not be satisfied or waived, including governmental or stockholder approvals.
• A governmental entity may prohibit, delay, or refuse to grant approval for the transaction, or impose conditions, limitations, or restrictions.
• The proposed transaction may not be completed on the expected terms, timeframe, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company.
• Failure to realize the anticipated benefits of the proposed transaction, including synergies, due to delays or integration difficulties.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other legal proceedings may affect the timing or occurrence of the transaction or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the transaction.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs.
• Actions by third parties, including government agencies.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty in separating SpinCo's business from BD's other businesses.
• Disruption of management time from ongoing business operations due to the pendency of the transaction.
• Other effects of the pendency of the transaction on relationships with employees, customers, suppliers, or other counterparties.
• The credit ratings of the combined company could decline following the acquisition.
• The announcement or consummation of the proposed acquisition could have a negative effect on the market price of Waters and BD's capital stock or on their operating results.

Future Outlook

The proposed transaction is expected to be completed following the special meeting of Waters stockholders on January 27, 2026, where they will vote on matters necessary to complete the merger. Waters anticipates strong revenue and cost synergy opportunities from the combination, including cross-selling products, promoting LC-MS in clinical diagnostics, and optimizing logistics and procurement. The combined company aims to implement its business strategy and realize these anticipated benefits, though subject to various risks and uncertainties.

Management Comments

• Waters believes that the disclosures set forth in the Proxy Statement/Prospectus comply fully with all applicable law, and that no further disclosure beyond that already contained is required.
• Waters believes it has meritorious arguments against the Complaints and the Demand Letters.
• Waters has determined to voluntarily supplement certain disclosures to moot these disclosure claims, minimize any risk of delay to the consummation of the Merger, and avoid the costs, risks, and uncertainties inherent in defending such lawsuits, without admitting any culpability, liability, or wrongdoing.
• Waters board of directors continues to recommend unanimously that you vote FOR the proposals being considered at the special meeting of Waters stockholders.

Industry Context

The proposed Reverse Morris Trust transaction positions Waters Corporation to expand its presence in the life sciences and diagnostics markets by integrating BD's Biosciences and Diagnostic Solutions business. This move reflects a broader industry trend of consolidation and strategic realignment among major players seeking to enhance market share, leverage complementary technologies (e.g., LC-MS in clinical diagnostics), and achieve operational efficiencies through synergies. The valuation analyses presented, including comparable company multiples and precedent transaction values, indicate a competitive landscape where strategic acquisitions are valued based on growth potential, synergy realization, and market positioning in high-growth segments like research and clinical diagnostics.

Comparison to Industry Standards

• Waters' implied equity value range of $20.9 billion to $24.7 billion and per share value of $348.11 to $410.57 (as of July 11, 2025) were derived using a DCF analysis with a discount rate of 9.0% to 10.0% and terminal exit multiples of 16.0x to 18.0x on NTM Adjusted EBITDA.
• The BDS Business's implied enterprise value range of $16.8 billion to $19.7 billion (standalone) and $19.6 billion to $23.1 billion (with synergies) used similar DCF parameters.
• Comparable companies analyzed for EV/Adj. EBITDA multiples (2025E/2026E) include Thermo Fisher Scientific (17.7x/16.2x), Danaher Corporation (21.0x/19.2x), Agilent Technologies, Inc. (18.4x/16.9x), Mettler Toledo (22.5x/20.9x), and Bio-Techne Corporation (19.5x/17.6x). Waters' own multiples were 20.0x/18.6x for 2025E/2026E, placing it among the higher-valued comparables.
• Selected precedent transactions, such as Danaher's acquisition of General Electric's Biopharma business (~$20.0 billion, ~18.5x LTM Multiple) and Thermo Fisher's acquisition of Life Technologies (~$15.7 billion, ~13.7x LTM Multiple), provide context for transaction valuations in the life sciences and diagnostics sectors, with multiples ranging widely based on specific deal characteristics and market conditions.

Legal Proceedings

• Two lawsuits filed by purported stockholders in the Supreme Court of the State of New York, New York County: Ryan Carroll v. Waters Corporation, et al., No. 650159/2026 and Joseph Clark v. Waters Corporation, et al., No. 650180/2026.
• Demand letters received from purported stockholders.
• Allegations in both lawsuits and demand letters claim the Proxy Statement/Prospectus omitted certain purportedly material information, rendering it incomplete and misleading.

Stakeholder Impact

• Shareholders: Required to vote on the merger, impacted by potential litigation outcomes, and the long-term value creation from the combined entity.
• Employees: Potential impact on retention of key personnel due to the merger and integration process.
• Customers and Suppliers: Potential disruption to existing relationships due to the pendency of the transaction and integration of businesses.
• Creditors: The combined company's indebtedness and credit ratings could be affected by the proposed acquisition and its financing.

Next Steps

• Waters stockholders will hold a special meeting on January 27, 2026, to vote on the proposals necessary to complete the Merger.
• The parties will work towards satisfying or waiving remaining closing conditions for the transaction.

Key Dates

Keywords

Waters Corporation, Becton Dickinson, BD Biosciences, Diagnostic Solutions, Merger, Acquisition, Reverse Morris Trust, Spin-Off, SEC Filing, Form 8-K, Proxy Statement, Stockholder Litigation, Financial Projections, Valuation, Life Sciences, Analytical Instruments, Healthcare Diagnostics